Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - Boston Therapeutics, Inc. | exh10_1.htm |
| EX-4.4 - EXHIBIT 4.4 - Boston Therapeutics, Inc. | exh4_4.htm |
| EX-4.3 - EXHIBIT 4.3 - Boston Therapeutics, Inc. | exh4_3.htm |
| EX-4.2 - EXHIBIT 4.2 - Boston Therapeutics, Inc. | exh4_2.htm |
| EX-4.1 - EXHIBIT 4.1 - Boston Therapeutics, Inc. | exh4_1.htm |
| EX-31.1 - EXHIBIT 31.1 - Boston Therapeutics, Inc. | exh31_1.htm |
| 10-Q - BOSTON THERAPEUTICS, INC. 10-Q - Boston Therapeutics, Inc. | boston10q.htm |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Boston Therapeutics, Inc. (the “Company”) for the quarter ending June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Carl. W. Rausch, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
|
(1)
|
The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
Dated: August 15, 2016
|
By:
|
/s/ Carl. W. Rausch
|
|
|
|
Carl. W. Rausch
|
|
|
|
|
Chief Executive Officer (Principal Executive, Financial and Accounting Officer)
|
|
|